Experimental CAR t combo trial halted early – only 2 patients enrolled
NCT ID NCT05714345
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding an extra drug (ALLO-647) to standard chemotherapy before a special immune cell treatment (CAR T) could help adults with a hard-to-treat type of lymphoma. Only 2 people joined before the trial was stopped early. The goal was to see if the new combination improved cancer control compared to chemo alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitair Ziekenhuis Brussel
Brussels, 1090, Belgium
-
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky, 40202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma
- New hope for lymphoma patients: glofitamab combo faces standard care in trial
- Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
- Affordable CAR-T breakthrough: academic therapy offers new hope for blood cancer patients
- Experimental donor CAR-T therapy tested in lymphoma – trial halted early